Bristol Myers Squibb’s Deucravacitinib Impresses in Phase 3 Psoriasis Trial
By Daniel Ojeda, Ph.D. On November 3rd, Bristol Myers Squibb reported results for Deucravacitinib in Phase 3 clinical trial in patients with moderate to severe plaque psoriasis. Treatment with Deucravacitinib …
Read More